William D Fisher

Summary

Country: Canada

Publications

  1. ncbi request reprint New oral anticoagulants and outpatient prophylaxis of venous thromboembolism
    William D Fisher
    Department of Surgery, McGill University Health Centre, Montreal, Quebec, Canada
    Am J Manag Care 17:S15-21. 2011
  2. doi request reprint Extended venous thromboembolism prophylaxis in patients undergoing hip fracture surgery - the SAVE-HIP3 study
    W D Fisher
    McGill University Health Centre, 1650 Cedar Avenue, Bureau B5 158 7, Montreal, Quebec H3G 1A4, Canada
    Bone Joint J 95:459-66. 2013
  3. ncbi request reprint Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies
    William D Fisher
    McGill University Health Centre, 1650 Cedar Avenue, Montreal, Quebec, H3G 1A4, Canada
    Thromb Haemost 97:931-7. 2007
  4. pmc Outpatient thromboprophylaxis after hip or knee surgery: discrepancies and concerns
    William D Fisher
    McGill University Health Centre, Montreal, Que
    CMAJ 178:1571-2. 2008
  5. pmc Impact of venous thromboembolism on clinical management and therapy after hip and knee arthroplasty
    William D Fisher
    Department of Orthopaedic Surgery, McGill University Health Centre, Montreal, Que
    Can J Surg 54:344-51. 2011
  6. ncbi request reprint Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery
    Wolfgang Mueck
    Clinical Pharmacology, Bayer HealthCare AG, Aprather Weg 18a, Wuppertal, Germany
    Clin Pharmacokinet 47:203-16. 2008

Detail Information

Publications6

  1. ncbi request reprint New oral anticoagulants and outpatient prophylaxis of venous thromboembolism
    William D Fisher
    Department of Surgery, McGill University Health Centre, Montreal, Quebec, Canada
    Am J Manag Care 17:S15-21. 2011
    ..These drugs, which include dabigatran, apixaban, and rivaroxaban, should encourage improved compliance with guideline recommendations for optimal duration of thromboprophylaxis and lead to a reduced incidence of venous thrombolic events...
  2. doi request reprint Extended venous thromboembolism prophylaxis in patients undergoing hip fracture surgery - the SAVE-HIP3 study
    W D Fisher
    McGill University Health Centre, 1650 Cedar Avenue, Bureau B5 158 7, Montreal, Quebec H3G 1A4, Canada
    Bone Joint J 95:459-66. 2013
    ..TEAE rates were similar in both groups. In conclusion, the SAVE-HIP3 study results demonstrate that patients undergoing hip fracture surgery benefit from extended thromboprophylaxis...
  3. ncbi request reprint Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies
    William D Fisher
    McGill University Health Centre, 1650 Cedar Avenue, Montreal, Quebec, H3G 1A4, Canada
    Thromb Haemost 97:931-7. 2007
    ..Overall, rivaroxaban total daily doses of 5-20 mg had the most favorable balance of efficacy and safety, relative to enoxaparin, for the prevention of VTE after major orthopaedic surgery...
  4. pmc Outpatient thromboprophylaxis after hip or knee surgery: discrepancies and concerns
    William D Fisher
    McGill University Health Centre, Montreal, Que
    CMAJ 178:1571-2. 2008
  5. pmc Impact of venous thromboembolism on clinical management and therapy after hip and knee arthroplasty
    William D Fisher
    Department of Orthopaedic Surgery, McGill University Health Centre, Montreal, Que
    Can J Surg 54:344-51. 2011
    ..Furthermore, the direct Factor Xa inhibitor rivaroxaban has been shown to be more effective than enoxaparin in preventing VTE...
  6. ncbi request reprint Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery
    Wolfgang Mueck
    Clinical Pharmacology, Bayer HealthCare AG, Aprather Weg 18a, Wuppertal, Germany
    Clin Pharmacokinet 47:203-16. 2008
    ....